GLPG0187 was developed for metastatic cancer.
In the trial, Galapagos expects to involve patients with solid tumor s and patients with confirmed diagnosis of advanced, recurrent, or metastatic cancer who are refractory to standard therapy or for whom no standard therapy exists, are eligible to enroll in the trial.
The primary endpoint of the trial is to investigate the safety and tolerability of the drug during the period of four weeks in cancer patients.
The secondary endpoint of the trial will involve pharmacokinetics and pharmacodynamics (CTX biomarker) of the candidate drug and preliminary antitumor effects of GLPG0187 according to RECIST 1.1, the standard endpoint for cancer clinical trials.
Galapagos said the Phase I clinical study for GLPG0187 in healthy volunteers demonstrated good safety and a promising biomarker profile.